Fremanezumab Managed Access Program for Pediatric Patients
Fremanezumab (TEV-48125) Compassionate Use Program for Pediatric Patients (6 to 17 Years) With Chronic or Episodic Migraine
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Expanded Access Type
Expanded Access Type
- Individual Patients: Allows a single patient, with a serious disease or condition who cannot participate in a clinical trial, access to a drug or biological product that has not been approved by the FDA. This category also includes access in an emergency situation.
- Intermediate-size Population: Allows more than one patient (but generally fewer patients than through a Treatment IND/Protocol) access to a drug or biological product that has not been approved by the FDA. This type of expanded access is used when multiple patients with the same disease or condition seek access to a specific drug or biological product that has not been approved by the FDA.
- Treatment IND/Protocol: Allows a large, widespread population access to a drug or biological product that has not been approved by the FDA. This type of expanded access can only be provided if the product is already being developed for marketing for the same use as the expanded access use.
- Individual Patients
Contacts and Locations
Study Contact
Study Contact
- Name: Teva Medical Expert, MD
- Phone Number: 1-888-483-8279
- Email: USMedInfo@tevapharm.com
Study Locations
-
-
-
Brugge, Belgium
- Teva Investigational Site 37096
-
Brussels, Belgium, 1090
- Teva Investigational Site 37093
-
Hasselt, Belgium, 3500
- Teva Investigational Site 37095
-
Liege, Belgium, 4000
- Teva Investigational Site 37094
-
-
-
-
-
Calgary, Canada
- Teva Investigational Site 11149
-
-
Ontario
-
Newmarket, Ontario, Canada, L3Y5G8
- Teva Investigational Site 11151
-
Sarnia, Ontario, Canada, N7T 4X3
- Teva Investigational Site 11152
-
-
-
-
-
Brno, Czechia, 602 00
- Teva Investigational Site 54170
-
Ostrava-Moravska, Czechia, 702 00
- Teva Investigational Site 54181
-
Pardubice, Czechia, 530 02
- Teva Investigational Site 54171
-
Prague, Czechia
- Teva Investigational Site 54172
-
Prague 6, Czechia, 160 00
- Teva Investigational Site 54167
-
Praha 8, Czechia, 186 00
- Teva Investigational Site 54182
-
Rychnov nad Kneznou, Czechia, 516 01
- Teva Investigational Site 54173
-
-
-
-
-
Firenze, Italy, 50134
- Teva Investigational Site 30206
-
Rome, Italy, 00128
- Teva Investigational Site 30211
-
-
-
-
-
Barcelona, Spain, 08029
- Teva Investigational Site 31247
-
Pamplona, Spain, 31008
- Teva Investigational Site 31240
-
Valencia, Spain, 46010
- Teva Investigational Site 31249
-
Zaragoza, Spain, 50009
- Teva Investigational Site 31238
-
-
-
-
-
Stockholm, Sweden, 112 81
- Teva Investigational Site 42059
-
-
-
-
-
Hull, United Kingdom, HU3 2JZ
- Teva Investigational Site 34239
-
Oxford, United Kingdom, OX3 9DU
- Teva Investigational Site 34237
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Eligible patients may enter this CUP after successfully completing TV48125-CNS-30084 and all End of Study procedures
- In the opinion of your physician/investigator are able to continue IMP (fremanezumab) in a safe and compliant way.
Exclusion Criteria:
- Additional criteria may apply, please contact your physician/investigator for more information.
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TV48125-CNS-80005
- TV48125-MH-80011 (Other Identifier: Sponsor)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.